Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583634 | 0.83 | KMT2A (0.38) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL1351011 | 0.77 | LATS1 (0.37) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL19706901 | 0.76 | GHSR (0.40) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL28302110 | 0.76 | KMT2A (0.39) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL2781817 | 0.74 | OPRM1 (0.42) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL2746842 | 0.74 | GHSR (0.36) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL15903847 | 0.74 | CYP1A2 (0.46) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL13525930 | 0.72 | KMT2A (0.38) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL10040060 | 0.72 | KMT2A (0.38) | MEN1ALDH1A1TSHRKMT2ACYP1A2 | |
| SCHEMBL298008 | 0.72 | KMT2A (0.38) | MEN1ALDH1A1TSHRKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209020-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) | 2024-06-27 | — | — | US | disclosed |
| WO-2021085635-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | 学校法人中部大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209020-A1 | REACTION AGENT FOR AMIDE REACTION AND METHOD FOR PRODUCING AMIDE COMPOUND USING SAME | NAAA, FAAH, FAAH2 | MEN1 1214/4885ALDH1A1 386/4885TSHR 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.